Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Gastroenterology
Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Ulcerative Colitis Research Study
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Do you have Ulcerative Colitis?
Ulcerative Colitis
Ulcerative Colitis? Research Study
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Dysbiosis in inflammatory bowel disease.
Mind/Body Medicine and IBD Flare-up
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Do you suffer from Ulcerative Colitis?
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Investigational Drug Vedolizumab (MLN0002) for Adults with Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Just hanging in there with your Ulcerative Colitis?
How do UC Life?
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Children and Adolescents with Mildly-to-Moderately Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid Refractory Ulcerative Colitis [291-415]
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid Refractory Ulcerative Colitis [291-415]
A Phase I, Blinded, Multicenter, Dose-escalation, Placebo-controlled, Single-dose Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Patients with Active Ulcerative Colitis [MDX1100-01]
A Phase I, Multicenter, Dose-escalation, Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Patients with Active Ulcerative Colitis [MDX1100-01]
Active Ulcerative Proctitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Efficacy and safety of new oral budesonide-MMX™ (CB-01-02) 6 mg and 9 mg extended release tablet formulations in patients with mild or moderate, active ulcerative colitis. A multicenter, randomized, double-blind, double dummy comparative study versus placebo, with an additional reference arm evaluating Asacol® 2400 mg.
M06-826 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Do you have ulcerative colitis in remission?
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
An Ulcerative Colitis Research Study
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis - Houston, TX
Moderate to Severe Ulcerative Colitis
(CB-01-02/01)Randomized Placebo Controlled Trial of Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg in Patients With Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of XXXXXXXXX Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis.
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
